Cryoprecipitate therapy in amniotic fluid embolization

Rodgers, Griffin P.; Heymach, George J.

doi:10.1016/0002-9343(84)91009-x

Cited by 22 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, since cryoprecipitate contains fibronectin, it could facilitate the removal of cellular and particulate matter, such as amniotic fluid debris, from the blood via the monocyte/macrophage system. 46,131 Recently, recombinant activated factor VIIa has been used to manage severe DIC resistant to conventional blood product replacement in women with AFE. 132,133 Uterine bleeding in a woman already delivered can be controlled by massage and use of intravenous oxytocin.…”

Section: Treatmentmentioning

confidence: 99%

Amniotic fluid embolism: an evidence-based review

Conde-Agudelo

Romero

2009

American Journal of Obstetrics and Gynecology

240

277

View full text Add to dashboard Cite

We conducted an evidence-based review of information bout amniotic fluid embolism (AFE). The estimated incidence of AFE is 1:15,200 and 1:53,800 deliveries in North America and Europe, respectively. The case fatality rate and perinatal mortality associated with AFE are 13–30% and 9–44%, respectively. Risk factors associated with an increased risk of AFE include advanced maternal age, placental abnormalities, operative deliveries, eclampsia, polyhydramnios, cervical lacerations, and uterine rupture. The hemodynamic response in AFE is biphasic, with initial pulmonary hypertension and right ventricular failure, followed by left ventricular failure. Promising therapies include selective pulmonary vasodilators and recombinant activated facto Vlla. Important topics for future research are presented.

show abstract

Section: Treatmentmentioning

confidence: 99%

Amniotic fluid embolism: an evidence-based review

Conde-Agudelo

Romero

2009

American Journal of Obstetrics and Gynecology

240

277

View full text Add to dashboard Cite

show abstract

“…Other ancillary treatment modalities include inhaled nitric oxide, high-dose corticosteroids, and epinephrine. 36,37 Conclusion AFE remains one of the most feared and lethal complications of pregnancy. As a result of its variable presentation, unpredictability, and lack of confirmed diagnostic modalities, clinical suspicion on behalf of the anesthesiologist remains paramount.…”

Section: Managementmentioning

confidence: 99%